PS230005 Control-IQ 1.5 Post-Approval Study
← catalyst calendarSponsored by Tandem Diabetes Care, Inc. (industry) · TNDM — their whole pipeline →. With University of California, San Diego.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
144actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-30 | actual | When the study began enrolling |
| Primary completion | 2026-08-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-11 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 1 Diabetes
Intervention
- Device: Control-IQ Technology v1.5
Primary outcomes
what the primary-completion date above is the date OFIncidence Rates of Severe Hypoglycemia (SH)
measured 12 months
Incidence Rates of Diabetic Ketoacidosis (DKA)
measured 12 months
Permalink · TNDM's whole pipeline · Catalyst calendar · Every registered study · What changed